| ¼ò½é£º
                                                 
	²¿·ÝÖÐÎÄNeolamin 3B´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£© 
	Ó¢ÎÄÃû£ºThiamine Disulfide/Pyridoxine Hydrochloride/Hydroxocobalamin Acetate 
	É̱êÃû£ºNeolamin 3B Intravenous 
	ÖÐÎÄÃû£ºÁò°·ËضþÁò»¯Îï/ÑÎËáßÁ¶ß´¼/´×ËáôÇîܰ·Ëؾ²×¢Óà 
	Éú²úÉÌ£ºÈÕ±¾»¯Ëa 
	Ò©Îï·ÖÀàÃû³Æ 
	Éñ¾¼¡È⹦Äܼ¤»î¼Á 
	Å·ÎÄÉ̘ËÃû 
	Neolamin 3B Intravenous 
	1.Ò»°ãÃû£º¥Á¥¢¥ß¥ó¥¸¥¹¥ë¥Õ¥£¥É(ÂԺŠTDS) 
	 (Thiamine Disulfide) 
	»¯Ñ§Ãû£ºN ,N '-{Dithiobis¡²2-(2-hydroxyethyl)-1-methyl-2,1-ethenediyl¡³}bis{N -¡²(4-amino-2-methyl-5-pyrimidinyl)methyl¡³formamide} 
	·Ö×Óʽ£ºC24H34N8O4S2  
	·Ö×ÓÁ¿£º562.71 
	˜‹Ôìʽ£º 
	ÐÔ×´£º 
	Áò°·ËضþÁò»¯ÎïΪ°×É«ÖÁdz»Æ°×É«·ÛÄ©£¬ÎÞÆøÎ¶»òÂÔ´øÒìζ£¬Î¶Î¢¿à¡£ 
	ÄÑÈÜÓÚÒÒ´¼£¨95£©£¬¼¸ºõ²»ÈÜÓÚË®»òÒÒÃÑ¡£ Ëü¿ÉÈÜÓÚÏ¡ÑÎËá»òÏ¡ÏõËá¡£ ±¥ºÍË®ÈÜÒº¼¸ºõÊÇÖÐÐԵġ£ 
	2. Ò»°ãÃû£º¥Ô¥ê¥É¥¥·¥ó‰cËá‰c 
	(Pyridoxine Hydrochloride) 
	»¯Ñ§Ãû£º4,5-Bis(hydroxymethyl)-2-methylpyridine-3-ol monohydrochloride 
	·Ö×Óʽ£ºC8H11NO3・HCl 
	·Ö×ÓÁ¿£º205.64 
	˜‹Ôìʽ£º 
	ÐÔ×´£º 
	ÑÎËáßÁ¶ß´¼Êǰ×É«ÖÁ΢»ÆÉ«½á¾§·ÛÄ©¡£ 
	ËüÒ×ÈÜÓÚË®£¬ÄÑÈÜÓÚÒÒ´¼£¨99.5£©£¬¼¸ºõ²»ÈÜÓÚÒÒËáôû£¬ÒÒËᣨ100£©¡£ 
	ËüËæ×ŹâÖ𽥱仯¡£ 
	3. Ò»°ãÃû£º¥Ò¥É¥í¥¥½¥³¥Ð¥é¥ß¥óõ¡Ëá‰c 
	(Hydroxocobalamin Acetate) 
	»¯Ñ§Ãû£ºCoα-[α-(5,6-Dimethylbenz-1H -imidazol-1-yl)]-Coβ-hydroxocobamide monoacetate 
	·Ö×Óʽ£ºC62H89CoN13O15P・C2H4O2  
	·Ö×ÓÁ¿£º1406.41 
	˜‹Ôìʽ£º 
	ÐÔ×´£º 
	Hydroxocobalamin acetateÊÇÒ»ÖÖÉîºìÉ«¾§Ìå»ò·ÛÄ©£¬Ã»ÓÐÆøÎ¶¡£ 
	ËüÒ×ÈÜÓÚË®£¬¼¸ºõ²»ÈÜÓÚÒÒ´¼£¨95£©£¬¼¸ºõ²»ÈÜÓÚÒÒÃÑ¡£ 
	Ëü¾ßÓÐÎüʪÐÔ¡£ 
	Ò©ÓÃÒ©Àíѧ 
	1.ÐÂÉúËØ·Ì×¹ÜÈÜÒº¶ÔÉñ¾ÔÙÉúµÄÓ°Ïì 
	ʹÓôóÊóµÄµçÉúÀíѧ·½·¨¼ì²éÐÂÉúËØ·Ì×¹ÜÈÜÒº¶Ô×ø¹ÇÉñ¾¼·Ñ¹ÒýÆðµÄÉñ¾ËðÉËÓúºÏ¹ý³ÌµÄÓ°Ï죬½á¹û£¬ÐÂÉúËØ·Ì×¹ÜÈÜÒº±»¼Óѹ ËäÈ»Ëü²»»áÓ°ÏìÍËÐÐÐÔÉñ¾µÄÍËÐÐÐÔ½øÕ¹£¬µ«Ëü±»ÈÏΪ¿ÉÒÔ´Ù½øÉñ¾Ö§ÅäµÄ»Ö¸´¡£ 
	2. Neoramine·Sleeve Solution¶Ô±ûÏ©õ£°·Öж¾ÐÔÉñ¾Ñ×µÄÓ°Ïì2£©Neoramine·Sleeve SolutionºÍʹÓôóÊóµÄ¸÷»îÐԳɷֵÄЧ¹û 
	£¨1£©¹Û²ìÒ»°ãÖ¢×´µÄ±ä»¯£¬ 
	£¨2£©Éñ¾´«µ¼ËٶȲâÁ¿¡£ 
	£¨1£©¶þÁò»¯Áò°·£¬ÑÎËáßÁ¶ß´¼£¬ôÇîܰ·ºÍNeoramin-SuribiÈÜÒºÒÖÖÆ±ûÏ©õ£°·Öж¾´óÊóµÄËÀÍö£¬ÆäЧ¹û±»ÈÏΪÊÇ×îÇ¿µÄNeoramin-SuribiÈÜÒº¡£ÎªµÄÒì³£Ö¢×´µÄ±í´ïÿÖÖάÉúËØºÍNeoramin-SuribiÈÜÒº±ûÏ©õ£°·Öж¾ÏÔʾÕë¶Ô±ûÏ©õ£°·Í£Ò©ºó»Ö¸´Ö¢×´Ã»ÓÐÃ÷ÏÔµÄÒÖÖÆ×÷Ó㬴ٽøÔÚËùÓÐËĸö×éÖй۲쵽µÄ»Ö¸´£¬ÓÈÆäÊÇÔÚNeolamine·SleeveÒºÌå×éÖзdz£³öÉ«¡£ 
	ΪÁËÔÚÉñ¾´«µ¼ËÙ¶ÈÓÉÓÚ±ûÏ©õ£°·Ïà¶ÔÔö¼ÓµÄÒÖÖÆÐ§¹û 
	£¨2£©´óÊóµÄÔö³¤£¬Neoramin-SuribiÈÜÒºÏÔÖøÒÖÖÆ£¨4ÖÜ£©£¬Ò²´Ù½øÍ£Ò©±ûÏ©õ£°·¸øÒ©ºóµÄ»Ö¸´¡£ 
	3.Éñ¾²¡Àíѧ¼ìË÷ 
	άÉúËØBȺ¶Ô´óÊó±ûÏ©õ£°·Éñ¾Ñ×µÄÒÖÖÆ×÷ÓõÄ×é֯ѧͼÏñµÄ¶¨Á¿Ñо¿±íÃ÷£¬ÓÐËèÇÊÏËάµÄ±äÐγ̶ȺÍËèÇÊÃæ»ýÓëËèÇÊÏËÎ¬Ãæ»ýµÄ±ÈÀýÔÚneolamin / ÓÐËèÏËάºá½ØÃæ»ý£¬µ¥Î»Ãæ»ý£¬µ¥Î»Ãæ»ýÍËÐÐÐÔÓÐËèÏËάÊý£¬Seavanϸ°ûºËÊý£¬µç×ÓÏÔ΢¾µ¹Û²ì¼°Ñü׵ǰ½Çϸ°ûRNAº¬Á¿µÄ·Ö²¼ ¹Û²ìµ½ÒÖÖÆÇ÷ÊÆ¡£ 
	ÊÊÓ¦Ö¢ 
	¡ðµ±Ò©ÎïÖк¬ÓеÄάÉúËØÐèÇóÔö¼ÓÇÒ½øÊ³²»×ãʱ£¬¹©Ó¦£¨ÏûºÄÐÔ¼²²¡£¬Ôи¾£¬²¸ÈéÆÚ¸¾Å®µÈ£© 
	¡ðÍÆ²âÔÚÒÔϼ²²¡ÖУ¬Éæ¼°¸ÃÒ©ÎïÖк¬ÓеÄάÉúËØµÄȱ·¦»ò´úлÎÉÂÒ 
	¡ñÉñ¾Í´ 
	¡ñ¼¡ÈâÌÛÍ´·¹Ø½ÚÍ´ 
	¡ñÖÜΧÉñ¾Ñ×·ÖÜΧÉñ¾Âé±Ô 
	¼´Ê¹Ã»ÓÐЧ¹û£¬Ò²²»Ó¦Ëæ±ãÔÚÔÂÇòÉÏʹÓᣠ
	Ó÷¨ÓëÓÃÁ¿ 
	ÿÌ컺Âý¾²Âö×¢Éä10mLÆÕͨ³ÉÈË¡£ÁíÍ⣬Ӧ¸ù¾ÝÄúµÄÄêÁäºÍÖ¢×´Ôö¼Ó»ò¼õÉÙ¡£ 
	°ü×° 
	10°²ê³£¬50°²ê³ 
	Éú²úÉÌ£ºÈÕ±¾»¯Ëa 
	ÍêÕû´¦·½×ÊÁϸ½¼þ£ºhttp://www.info.pmda.go.jp/go/pack/3179504A1116_1_12/ 
	Neolamin 3B Intravenous£¨Thiamine Disulfide/Pyridoxine Hydrochloride/Hydroxocobalamin Acetate£© 
	Name of drug classification 
	Neuromuscular function activator 
	Sales name 
	Neoramine · Sleeve Solution (for intravenous injection) 
	composition 
	Neoramine · Sleeve Solution (for intravenous injection) contains the following ingredients in 10 mL of 1 tube. 
	Active ingredient · content 
	Thiamine disulfide 50 mg 
	Pyridoxine hydrochloride 100 mg 
	As hydroxocobalamin acetate acetate hydroxocobalamin 1, 000 μg 
	Additive/content 
	Urea 50 mg 
	pH regulator 
	Contraindication 
	Patients with a history of hypersensitivity to this drug and thiamine disulfide 
	Indication or effect 
	¡ð Supply (consumable diseases, pregnant women, nursing women, etc.) when demand for vitamins contained in this drug increases and ingestion from meals is insufficient 
	¡ð It is presumed that, among the following diseases, deficiency or metabolic disorder of vitamins contained in this drug is involved 
	¡ñ Neuralgia 
	¡ñ Muscle pain · arthralgia 
	¡ñ peripheral neuritis · peripheral nerve paralysis 
	Should not be used casually over the moon even though there is no effect. 
	Slowly intravenously inject 10 mL of usual adult once a day. 
	Incidentally, it should be increased or decreased according to your age and symptoms 
	Serious side effects 
	Shock (<0.1%), anaphylactoid symptoms 
	Shock, anaphylactoid-like symptoms may occur, so if you have general skin skin flushing, itching, blood pressure decrease, chest tightness, dyspnoea, convulsions etc. appear immediately, discontinue administration and take appropriate measures about. 
	Medicinal pharmacology 
	Effect of neolamine · Sleeve's solution on nerve regeneration 
	As a result of investigating the effect of neolamine · Sleeve's solution on the healing process of neuropathy due to sciatic nerve crush by electrophysiological method using rat, neoramine · Sleeve's solution does not affect degenerative progression of crush nerve, It is considered to promote the recovery of innervation. 
	Effect of neolamine · Sleeve's solution on acrylamide toxic neuritis 
	Using rats, the effect of neolamine · Sleeve's solution and its respective active ingredients 
	(1) observation of changes in general symptoms, 
	(2) nerve conduction velocity measurements. 
	Thiamine disulfide, pyridoxine hydrochloride, hydroxocobalamin and neolamine · Sleeve solution inhibit the death of acrylamide intoxicated rats, but Neoramine · Sleeve's solution is considered to be the most effective. For the expression of abnormal symptoms of acrylamide poisoning, each vitamin and neolamine · sleevy liquid did not show obvious inhibitory effect, but recovery of symptoms after the discontinuation of acrylamide was found to promote recovery in all 4 groups, It was remarkable in Neolamine · Sleeve liquid group. 
	Neoramine/Sleeve's solution significantly inhibited (4 th week) against the inhibitory action of acrylamide against the increase in nerve conduction velocity associated with the growth of rat and promoted recovery after discontinuation of acrylamide administration. 
	Neuropathological search 
	Quantitative studies of histological images of the inhibitory effect of vitamin B group on rat acrylamide neuritis revealed that the degree of deformity of myelinated fibers and the ratio of myelin sheath area and myelinated fiber area in neolamin / The distribution of cross-sectional area of myelinated fibers, the interstitial area, the number of degenerative myelinated fibers in the unit area, the number of nuclei of Seavan cells, the electron microscopic observation and the RNA amount in the lumbar cord anterior horn cells A tendency of suppression was observed. 
 |